Typic adverse reactions from chemotherapy in cancer patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The issues of chemotherapy remain the most difficult, because it is perhaps practically impossible to carry out drug therapy correctly, observing the main ethical principle of a doctor – do no harm. One of the main principles of chemotherapy is based on stopping cell replication, destroying their growth and vital activity, which is undoubtedly associated with an impact on healthy cells, the life cycle of which, depending on histological characteristics, may vary from several days to several weeks and months, which, in any case, implies an inevitable damaging effect on various organ and tissue systems. The more aggressive the chemotherapy, the more complex the combinations used, the greater the damaging consequences. Knowing the most vulnerable targets, the mechanisms of their development, it is possible to correct the most dangerous risks and prevent undesirable consequences. Accumulated experience with chemotherapy allows us to predict the most dangerous risks arising both during therapy, from chronic diseases that reduce quality of life, and after its completion, including delayed effects leading to death due to hidden, dangerous complications. Properly selected and timely complication prevention, comprehensive diagnostics of markers of pathological changes in vital organs, adjustments to therapy, and other measures are the fundamental principles of effective therapy. The main recommendations are regular visits to specialized physicians in related fields and patient compliance. Treatment for cancer patients does not end with their discharge from the hospital. Lifelong follow-up is required for patients who have completed therapy with a positive outcome.

About the authors

Liliya L. Shamal

Kuban State Medical University

Author for correspondence.
Email: levonna@list.ru
ORCID iD: 0009-0008-7694-1532
SPIN-code: 5074-9529

Cand. Sci. (Pharmacy)

Russian Federation, 4 Mitrofana Sedina st, Krasnodar, 350063

Roman A. Murashko

Kuban State Medical University; Clinical Oncology Dispensary No. 1

Email: murashko973@gmail.com
ORCID iD: 0000-0001-8873-8461
SPIN-code: 8484-2695

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, 4 Mitrofana Sedina st, Krasnodar, 350063; Krasnodar

Naira N. Markarova

Kuban State Medical University; Ekaterininskaya Clinic

Email: maddinea0@gmail.com
ORCID iD: 0009-0004-6014-8004
Russian Federation, 4 Mitrofana Sedina st, Krasnodar, 350063; Krasnodar

Gleb V. Simavonyan

Kuban State Medical University

Email: simavonyan.gleb345@gmail.com
ORCID iD: 0009-0001-9511-0370
Russian Federation, 4 Mitrofana Sedina st, Krasnodar, 350063

Pavel A. Galenko-Yaroshevsky

Kuban State Medical University

Email: galenko.yarochevsky@gmail.com
ORCID iD: 0000-0003-3190-1437
SPIN-code: 1575-6129

Dr. Sci. (Medicine), Professor, Corresponding of the Russian Academy of Sciences

Russian Federation, 4 Mitrofana Sedina st, Krasnodar, 350063

References

  1. Galenko-Yaroshevsky PA, Alekseenko SN, Gromova OA, et al. Oncological diseases. State of the problem, drugs and prospects for creating new biomarkers for personalized therapy. Krasnodar: Kuban State Medical University. 2024. 461 p. (In Russ.) EDN: FLBYQC
  2. Kozjavin NA, Mureyko EA, Nikiforov VS, et al. Anthracycline-induced cardiomyopathy in the long-term period after chemotherapy: clinical case. CardioSomatics. 2022;13(3):176–180. doi: 10.17816/CS133645 EDN: DRDOSB
  3. Shilov SN, Berezikova EN, Bobyleva ET, et al. Risk stratification and primary prevention of chemotherapy cardiotoxicity. Siberian Journal of Clinical and Experimental Medicine. 2024;39(4):187–193. doi: 10.29001/2073-8552-2024-39-4-187-193 EDN: BDJWWL
  4. Kanorsky SG, Galenko-Yaroshevsky PA, Alekseenko SN, et al. Atrial fibrillation: yesterday, today, tomorrow. Kuban Scientific Medical Bulletin. 2025;32(3):107–120. doi: 10.25207/1608-6228-2025-32-3-107-120 EDN: VIUSDN
  5. Potievskaya VI, Akhobekov AA, Bolotina LV, et al. Cardiovascular complications of antitumor therapy for breast cancer: diagnosis, prevention and treatment. Siberian Journal of Oncology. 2021;20(5): 138–148. doi: 10.21294/1814-4861-2021-20-5-138-148 EDN: TDQYQN
  6. Setia A, Challa RR, Vallamkonda B, et al. Nanomedicine and nanotheranostics: special focus on imaging of anticancer drugs induced cardiac toxicity. Nanotheranostics. 2024;8(4):473–496. doi: 10.7150/ntno.96846
  7. Kotamraju S, Chitambar CR, Kalivendi SV, et al. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002;277(19):17179–17187. doi: 10.1074/jbc.M111604200
  8. Chung WB, Youn HJ. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med. 2016;31(4):625–633. doi: 10.3904/kjim.2016.017
  9. García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, et al. Lipid-based nanoparticles: application and recent advances in cancer treatment. Nanomaterials. 2019;9(4):638. doi: 10.3390/nano9040638 EDN: UUEJYZ
  10. Dobrodeev AYu, Kostromitsky DN, Tarasova AS, et al. Short-term outcomes of neoadjuvant chemotherapy in colorectal cancer patients with isolated liver metastasis. Siberian Journal of Oncology. 2022;21(6):17–24. doi: 10.21294/1814-4861-2022-21-6-17-24 EDN: TDTHBO
  11. www.ncbi.nlm.nih.gov [Internet]. LiverTox: Clinical and research information on drug induced liver injury. Bethesda (MD): National institute of diabetes and digestive and kidney diseases; 2012. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548583
  12. Burnasheva EV, Shatokhin YuV, Snezhko IV, et al. Kidney injury in cancer therapy. Nephrology. 2018;22(5):17–24. doi: 10.24884/1561-6274-2018-22-5-17-24 EDN: YMQWDZ
  13. Gromova EG, Biryukova LS, Dzhumabaeva BT, et al. Practical recommendations for the correction of nephrotoxicity of antitumor drugs. Malignant Tumors. 2022;12(3S2):144–158. (In Russ.) doi: 10.18027/2224-5057-2022-12-3s2-144-158 EDN: QNQQDU
  14. Sergeeva NS, Karmakova TA, Savchina VV, et al. Dynamics of urinary kim-1 as a biomarker of acute kidney injury in cancer patients undergoing cisplatin-based chemotherapy. Siberian Journal of Oncology. 2023; 22(4):44–54. doi: 10.21294/1814-4861-2023-22-4-44-54 EDN: SBITKP
  15. Mikhalevich OK, Korenev DS. Analysis of the structure of complications after chemotherapy for breast cancer at the Clinical Regional Hospital of the Kaliningrad Region. In: HimBiSeasons. Collection of abstracts from the All-Russian Forum of Young Researchers. 2023. Kemerovo: Kemerovo State University; 2023. P. 127. (In Russ.) EDN: VIYPVC
  16. Grivtsova LYu, Larionova VB, Falaleeva NA. Immunocorrective treatment use in the prevention of hematological and infectious complications of chemotherapy in cancer patients. Oncohematology. 2021;16(4): 23–30. doi: 10.17650/1818-8346-2021-16-4-23-30 EDN: QQICJE
  17. Vykhovanets NYu, Aleshechkin PA, Tomash LA, et al. Early and long-term neurological complications of chemotherapy in oncology (literature review). Malignant tumors. 2022;12(4):41–49. doi: 10.18027/2224-5057-2022-12-4-41-49 EDN: JIYRGG
  18. Ostroumova OD, Shikh EV, Rebrova EV, et al. Drug-induced toxic optic neuropathy. Russian Annals of Ophthalmology. 2020;136(4):156–164. doi: 10.17116/oftalma2020136041156 EDN: HUGHNW
  19. Karpov SM, Babenko DV, Tambieva HK-S, et al. Nervous system damage in breast cancer patients receiving chemotherapy. Journal of Volgograd State Medical University. 2023;20(4):22–27. doi: 10.19163/1994-9480-2023-20-4-22-27 EDN: UFKKVT
  20. Polushin AYu, Krasnov VS, Bardakov SN, et al. Myelopathy associated with acute leukemia. Multidisciplinary view on the problem. Russian Neurological Journal. 2020;25(6):19–28. doi: 10.30629/2658-7947-2020-25-6-19-28 EDN: HIJHWE
  21. Murkamilov IT, Sabirov IS, Fomin VV, et al. Cerebrovascular complications in patients with malignant neoplasms. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(12):128–133. doi: 10.17116/jnevro2021121121128 EDN: YTHGBO
  22. Semiglazova TYu, Ponasenko OI, Lyashchenko VA, et al. Late complications of chemotherapy and hormone therapy in the treatment of breast cancer: general weakness, cognitive impairment, peripheral neuropathy, treatment-induced myeloproliferative diseases (part 1). Problems in Oncology. 2024;70(3):411–423. doi: 10.37469/0507-3758-2024-70-3-411-423 EDN: BYNVPY
  23. Iorio-Morin C, Gahide G, Morin C, et al. Management of primary central nervous system lymphoma using intra-arterial chemotherapy with osmotic blood-brain barrier disruption: retrospective analysis of the Sherbrooke cohort. Front Oncol. 2021;10:543648. doi: 10.3389/fonc.2020.543648 EDN: AVUXVX
  24. Kerckhove N, Collin A, Condé S, et al. Chemotherapy-induced peripheral neuropathy: symptomatology and epidemiology. Bull Cancer. 2018;105(11):1020–1032. doi: 10.1016/j.bulcan.2018.07.009
  25. Tkachenko EV, Andreev VV, Yatsenko AV, et al. Taxanes use and neurotoxicity in cancer patients. Bulletin of Neurology, Psychiatry and Neurosurgery. 2021;(2):107–116. doi: 10.33920/med-01-2102-03 EDN: GCQMNF
  26. Dinikina YV, Efimtsev AY, Chernova SI, et al. Subacute methotrexate-induced encephalopathy: features of diagnostics and treatment options. clinical case report. Pediatric Hematology/Oncology and Immunopathology. 2019;18(1):73–80. doi: 10.24287/1726-1708-2019-18-1-73-80 EDN: GBCVEM
  27. Zyablova EI, Nefedova LN, Porkhanov VA. Radiological imaging of adverse events to immunotherapy. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2020;3(3):44–53. doi: 10.37174/2587-7593-2020-3-3-44-53 EDN: AZWUML
  28. Zyablova EI, Krivitskaya EYu, Voronova IG. Pulmonary complications of cancer therapy. Innovative Medicine of Kuban. 2024;9(4):136–144. doi: 10.35401/2541-9897-2024-9-4-136-144 EDN: GPDBCB
  29. Dhamija E, Meena P, Ramalingam V, et al. Chemotherapy-induced pulmonary complications in cancer: significance of clinicoradiological correlation. Indian J Radiol Imaging. 2020;30(1):20–26. doi: 10.4103/ijri.IJRI_178_19 EDN: RRPSMM
  30. Nishino M, Hatabu H, Sholl LM, et al. Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care. Radiographics. 2017;37(5):1371–1387. doi: 10.1148/rg.2017170015 EDN: YHRLBF
  31. Johkoh T, Lee KS, Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021; 298(3):550–566. doi: 10.1148/radiol.2021203427 EDN: HKXVCU
  32. Suvyrina MB, Kim AG. Study of the state of the oral mucosa in squamous cell lung cancer after chemotherapy. In: Current problems and prospects for the development of dentistry in the north. Collection of articles from the interregional scientific and practical conference dedicated to the 25th anniversary of the Dentistry Department of the Medical Institute of the M.K. Ammosov North-Eastern Federal University. Yakutsk, 2021. P. 192–196. (In Russ.) EDN: XPHACD
  33. Makedonova YuA, Shkarin VV, Emelyanova OS, et al. Screening as a stage in the prevention of oral mucosal diseases in patients undergoing chemotherapy for malignant growths. Pediatric Dentistry and Dental Prophylaxis. 2023;23(4):336–345. doi: 10.33925/1683-3031-2023-689 EDN: RWDKTC
  34. Esiev RK, Shakhabova AR, Tsokova LV, et al. Oral pathologies in anticancer therapy: a literature review. Russian Journal of Dentistry. 2024;28(4):399–411. doi: 10.17816/dent631979 EDN: OWCILA
  35. Kazeko LA, Degtyareva MI. Some aspects of oral mukozite as complications of antitumor treatment. Medicine, Science and Education. 2021:78–81. (In Russ.)
  36. Ivanova AS, Obukhova OA, Kurmukov IA, et al. Review of ESPEN-2021 practice guidelines for patients with cancer. Part 2: interventions relevant to specific patient categories. Clinical Nutrition and Metabolism. 2022;3(4):193–206. doi: 10.17816/clinutr119059 EDN: TKPXSS
  37. Zheng P, Zhou C, Lu L, et al. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. J Exp Clin Cancer Res. 2022;41(1):271. doi: 10.1186/s13046-022-02485-0 EDN: DSFPMG
  38. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586): 1254–1261. doi: 10.1126/science.abf0529 EDN: LRZPSA
  39. Gohil VM. Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders. Expert Opin Investig Drugs. 2021;30(1):1–4. doi: 10.1080/13543784.2021.1840550 EDN: AZRZAL
  40. Lee JH, Cho YS, Jung KH, et al. Genipin enhances the antitumor effect of elesclomol in A549 lung cancer cells by blocking uncoupling protein-2 and stimulating reactive oxygen species production. Oncol Lett. 2020;20(6):374. doi: 10.3892/ol.2020.12237
  41. Ghosh P, Vidal C, Dey S, et al. Mitochondria targeting as an effective strategy for cancer therapy. Int J Mol Sci. 2020;21(9):3363. doi: 10.3390/ijms21093363 EDN: DZWMER
  42. Porporato PE, Filigheddu N, Pedro JMB, et al. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265–280. doi: 10.1038/cr.2017.155
  43. Huang J, Liu W, Kang W, et al. Effects of microbiota on anticancer drugs: current knowledge and potential applications. EBioMedicine. 2022;83:104197. doi: 10.1016/j.ebiom.2022.104197
  44. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. doi: 10.1200/JCO.21.01440 EDN: NKYGXZ
  45. Johkoh T, Lee KS, Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021; 298(3):550–566. doi: 10.1148/radiol.2021203427 EDN: HKXVCU

Copyright (c) 2025 Eco-Vector



 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».